Business
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
WILMINGTON, Del., November 07, 2025--Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/019a8e9e83684f4cf0f4cd4e0929e06c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GLcMKUaN.9aHm6E2YaWYWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/019a8e9e83684f4cf0f4cd4e0929e06c","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/2S0ltB2trX1U7vlBUcRmbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/019a8e9e83684f4cf0f4cd4e0929e06c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., November 07, 2025--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida.","length":471,"tagName":"p"},{"type":"text","content":"Hypereosinophilic Syndrome (HES) is a group of rare disorders characterized by persistent, significantly elevated levels of eosinophils (a type of white blood cell) in the blood and evidence of eosinophil-mediated organ or tissue damage.2 This may lead to progressive organ damage over time and if left untreated, may be fatal.2 Current treatments include glucocorticosteroids, chemotherapy medicines, tyrosine kinase inhibitors and an anti-interleukin-5 (IL-5) monoclonal antibody.2","length":483,"tagName":"p"},{"type":"text","content":"NATRON was a Phase III trial evaluating the efficacy and safety of FASENRA in patients with HES.3 Patients were randomized to receive either a single 30 mg subcutaneous injection of FASENRA or a placebo once every four weeks.3 The trial successfully met the primary endpoint, as treatment with FASENRA delayed the time to first HES worsening/flare and significantly reduced...